Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 09.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers |
| 31.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | usion of the hearing process. Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointme |
| 22.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Offi |
Stammdaten
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
Unternehmen & Branche
| Name | Aridis Pharmaceuticals, Inc. |
|---|---|
| Ticker | ARDS |
| CIK | 0001614067 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 8.915 USD |
| Beta | -26,04 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2023-09-30 | 10-Q | 417,000 | -83,000 | 0.00 | 6,534,000 | -11,802,000 |
| 2023-06-30 | 10-Q | 19,647,000 | 12,144,000 | 0.33 | 6,482,000 | -14,914,000 |
| 2023-03-31 | 10-Q | 1,082,000 | -6,816,000 | 9,434,000 | -27,882,000 | |
| 2022-12-31 | 10-K | 3,091,000 | -30,371,000 | 14,695,000 | -24,232,000 | |
| 2022-09-30 | 10-K | 399,000 | -5,176,000 | 12,120,000 | -32,863,000 | |
| 2022-09-30 | 10-Q | 399,000 | -8,239,000 | -0.47 | 12,120,000 | -35,823,000 |
| 2022-06-30 | 10-Q | 292,000 | -7,979,000 | -0.45 | 16,686,000 | -27,933,000 |
| 2022-06-30 | 10-K | 292,000 | -7,118,000 | 16,686,000 | -25,312,000 | |
| 2022-03-31 | 10-K | 1,187,000 | -7,582,000 | 23,817,000 | -19,641,000 | |
| 2022-03-31 | 10-Q | 1,187,000 | -7,766,000 | -0.44 | 23,817,000 | -20,409,000 |
| 2021-12-31 | 10-K | 1,535,000 | -42,193,000 | -3.77 | 26,796,000 | -13,110,000 |
| 2021-09-30 | 10-Q | 515,000 | -21,002,000 | 26,085,000 | -4,155,000 | |
| 2021-06-30 | 10-Q | 33,000 | -5,490,000 | 11,387,000 | -13,487,000 | |
| 2021-03-31 | 10-Q | 0 | -6,891,000 | -0.77 | 17,569,000 | -8,555,000 |
| 2020-12-31 | 10-K | 1,000,000 | -22,333,000 | -2.44 | 15,117,000 | -8,681,000 |
| 2020-09-30 | 10-Q | 1,000,000 | -5,786,000 | 12,106,000 | ||
| 2020-06-30 | 10-Q | 1,000,000 | -4,220,000 | 18,115,000 | ||
| 2020-03-31 | 10-Q | -6,504,000 | 22,007,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.